April 10, 2015November 9, 2015

Pharmaxis Presents Encouraging Phase 1 Results on COPD Therapy

COPD, News

Pharmaxis recently presented encouraging interim results regarding a single ascending dose stage phase I clinical trial that is evaluating its experimental therapy PXS4728A. The pharmaceutical company expects to offer the Semicarbazide-Sensitive Amine Oxidase/Vascular ... Read more

August 28, 2014November 11, 2015

Pharmaxis Ready to Start Test COPD and NASH Treatment on Humans

COPD, News

The chronic respiratory disorders pharmaceutical specialist Pharmaxis completed the development of its experimental drug, the Semicarbazide-Sensitive Amine Oxidase/Vascular Adhesion Protein-1 (SSAO/VAP-1) Inhibitor (PXS4728A), which is designed to treat several forms of chronic inflammation ... Read more